Pharma Stock Roundup AZN Voydeya Gets FDA Nod, MRK KRAS Inhibitor Enters Phase III - Zacks Investment Research
| J7Z Stock | EUR 116.85 1.15 0.97% |
Roughly 61% of Jazz Pharmaceuticals' investor base is looking to short. The analysis of current outlook of investing in Jazz Pharmaceuticals plc suggests that many traders are alarmed regarding Jazz Pharmaceuticals' prospects. The current market sentiment, together with Jazz Pharmaceuticals' historical and current headlines, can help investors time the market. In addition, many technical investors use Jazz Pharmaceuticals plc stock news signals to limit their universe of possible portfolio assets.
Jazz Pharmaceuticals stock news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Jazz daily returns and investor perception about the current price of Jazz Pharmaceuticals plc as well as its diversification or hedging effects on your existing portfolios.
Jazz |
Pharma Stock Roundup AZN Voydeya Gets FDA Nod, MRK KRAS Inhibitor Enters Phase III Zacks Investment Research
Read at news.google.com
 |
Jazz Pharmaceuticals Fundamental Analysis
We analyze Jazz Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Jazz Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Jazz Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Probability Of Bankruptcy
Probability Of Bankruptcy Comparative Analysis
Jazz Pharmaceuticals is currently under evaluation in probability of bankruptcy category among its peers. Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
Jazz Pharmaceuticals plc Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Jazz Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Jazz Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Jazz Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Jazz Pharmaceuticals Related Equities
| 0QF | Moderna | 4.41 | ||||
| 1FW1 | WUXI BIOLOGICS | 1.95 | ||||
| CSJ | CSL | 0.60 | ||||
| MBG | Mercedes Benz | 0.30 | ||||
| 22UA | BioNTech | 0.46 | ||||
| CSJA | CSL | 0.61 | ||||
| VX1 | Vertex Pharmaceuticals | 2.47 | ||||
| NOVA | Novo Nordisk | 19.28 |
Complementary Tools for Jazz Stock analysis
When running Jazz Pharmaceuticals' price analysis, check to measure Jazz Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jazz Pharmaceuticals is operating at the current time. Most of Jazz Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Jazz Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jazz Pharmaceuticals' price. Additionally, you may evaluate how the addition of Jazz Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges |